Jacob Van Naarden

Stories

Lilly's ovarian cancer ADC posts 79% response rate in platinum-sensitive disease

Leading Lilly's oncology division during Sofe-M development

Sofetabart mipitecan (Sofe-M) plus bevacizumab shrank tumors in 23 of 29 evaluable platinum-sensitive ovarian cancer patients, a 79.3% confirmed response rate. Every patient in the Phase 1 cohort had a response or stable disease, and the rate held in patients who had already taken a PARP inhibitor.

Updated Oct 26

FDA approves Jaypirca for previously untreated CLL/SLL

New Capabilities

Leads Jaypirca commercial strategy at Eli Lilly

The FDA on October 2 cleared Eli Lilly's Jaypirca for newly diagnosed chronic lymphocytic leukemia, the first non-covalent BTK inhibitor approved as initial therapy. The label covers adults without a known 17p deletion, roughly 92% to 95% of new cases.

Updated Oct 20

Notable Quotes

The standard of care for platinum-sensitive ovarian cancer has remained unchanged for a decade and demands new treatment options.

from Lilly's ovarian cancer ADC posts 79% response rate in platinum-sensitive disease · Updated Oct 26

This milestone underscores Jaypirca's versatility in the CLL continuum of care, from the first-line setting for appropriate patients to its valuable role in the relapsed or refractory post-covalent BTK inhibitor setting, reinforcing Jaypirca's broad applicability as a meaningful treatment option for people with CLL or SLL.

from FDA approves Jaypirca for previously untreated CLL/SLL · Updated Oct 20